As more companies replace labor with AI, a paper titled 'The AI Layoff Trap' has been released, addressing the impact of reduced consumption by laid-off workers on the market. Researchers warn that while AI automation may benefit individual companies, it could lead to excessive automation on a societal level. The paper was registered on arXiv on March 21, 2026, with a revised edition published in June. The key concept is 'demand externality', where the adoption of AI by one company leads to wage cost reductions, but the decrease in consumption by laid-off workers affects multiple companies. The researchers modeled the demand loss experienced by one company as 1/N when there are N companies. Consequently, they explained that the more intense the competition, the smaller the demand loss felt by individual companies, thus increasing the incentive to adopt AI. The paper proposes a Pigovian automation tax, arguing that taxing the demand loss not borne by companies could reduce the gap between private choices and collective outcomes. The researchers analyzed that UBI and capital income tax do not directly influence companies' automation decisions. This paper illustrates that discussions around AI and employment are expanding beyond mere job loss to encompass the relationship between macro demand and corporate profits.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.












Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.


